RSS

CYDY CytoDyn Inc

Mod: mightycydy Asst: HHIGambler,CaptnAmerca
Last Post: 4:33 PM
Followers: 439
Posts Today: 6
Views Today: 90824

CYDY Stock Quote & Tools

$0.2283 ▲ +0.0229 (+11.14%) As of Oct 16, 3:59 PM EDT
Last0.2283
$ Chg0.0229
Open0.2050
High0.2300
Beta1.4964
Year High0.397
Market Cap335.42M
P/B Ratio-2.68
EPS-0.04
Avg Vol (30d)1.68M
Volume3.96M
% Chg+11.14%
Prev Close0.2054
Low0.2050
VWAP0.21542
Year Low0.183
Total Shares1.47B
Shares Out1.47B
Float1.36B
ExchangeOTCQB
Healthcare Biotechnology & Life Sciences
Company Profile Buy Rating Time & Sales News Filings Financials

CYDY Stock Message Board Discussion

3 Pinned Posts
Leronlimab (Pro 140) Cliff Notes What is it? Leronlimab is a humanized monoclo (43) by trding
Leronlimab Regulator List (a work in progress) = upregulation = downregulation a-SMA (21) by ohm20
EIND: Information to Submit to Doctors Leronlimab a humanized monoclonal antibody binds CCR5, (38) by ohm20
  1. CaptnAmerca

    Tune in to hear Dr. Tony Fooch's presentation, titled "Trending Towards Irrelevance" Brought to

    (12)
  2. CTMedic

    MD Virologist, Can you post me to an article describing viral entry inhibition. I did not see

  3. hoops

    "Short Busting"

    (3)
  4. stevo180

    I think I read that the oncoimmune drug was not a typical MAB type large molecule and it is

    (2)
  5. CGC

    Hi all, Dr Patterson will be a speaker/panelist at the upcoming PMWC (Precision Medicine World

    (9)
  6. onestepahead

    I sold my Relief. I dont like the chances of approval for them. I also dont like the fact

    (2)
  7. sean007

    I see a reverse split in their future.......6-10 for 1....too many shares O/S.

  8. CDiddy

    Viral inhibitors won't be competition. Even after we get a handle on this, people won't go to the

    (2)
  9. ohm20

    If that's true but I have my doubts.

  10. MD VIROLOGIST

    It blocks viral entry. And aids in surfactant production with type 2 alveolar cells. Simple

    (1)
  11. CDiddy

    Oh, so it should be administered early on?

  12. ohm20

    The big one I remember off the top of my head is that it blocks viral

  13. CDiddy

    Can you elaborate? I am not super familiar, other than they had open label claims, and then

  14. CDiddy

    Huh?

  15. ohm20

    I'm still side eyeing RLF-100.The claims to what their drug actually does seems

    (1)
  16. chazzledazzle

    Current CDC says 90,000 Americans will die in the next 3 weeks. Think of it. 90,000. Damn.

  17. otcaddict

    CDiddy, you have to trust the doctor. I was watching a documentation on AMC and it could be very

    (5)
  18. CDiddy

    Do we have to do the pretend Bruce wants to talk to me thing again?

    (10)
  19. nmbr1stckpckr

    I've never been so bored waiting for the inevitable. That's how confident I am.

    (3)
  20. MD VIROLOGIST

    Ok let's talk in 2-4wks.

    (1)
  21. chazzledazzle

    Nothing at all wrong with RLFTH and CYDY saving lives. IMHO

    (2)
  22. MD VIROLOGIST

    Relief is a publically traded ADR, Neuro RX is private and a SPAC Big Rock has signed an agreement

    (1)
  23. CDiddy

    Easier to quantity thatn the binary quantification of dead or alive? Come on.

    (1)
  24. MD VIROLOGIST

    Sure, I have posted before why many studies eschewed mortality as an endpoint. I won't elaborate,

    (1)
  25. JLang

    Bingo... There's a reason the SPAC didn't go after Relief.. would be lucky to see 70 again.

  26. CDiddy

    There are no "issues" with using mortality as an endpoint. If there is, and you know that. Then

    (8)
  27. CDiddy

    I don't buy it. If they reduce mortality there is no reason to change the endpoint. There isn't

    (6)
  28. MD VIROLOGIST

    No,in the open label study there was a nine fold improvement in mortality. Of 319 drugs in current

    (2)
  29. Goosebumps

    There is a two week difference from completion of filled trial dates and they both share the same

    (2)
  30. CDiddy

    I'll predict they are used In mild to moderate due to cost, and LL for severe critical, because it

    (1)
  31. MD VIROLOGIST

    Yes they are, they changed endpoints mid trial because of the problems of using mortality, which I

    (2)
  32. CDiddy

    I read them. Just so you know this is a board for longs. We get a little defensive with new

    (2)
  33. CDiddy

    RLFTF is likely our primary competition. But even they are not going after

    (2)
  34. onestepahead

    If EUA takes a couple weeks I would hope amarex and Cytodyn get the mortality data with a EUA

  35. LaundryMoney

    So I'm not sure what to think here. The closest competitor for CYDY would be OncoImmune that was

    (5)
  36. CDiddy

    Welcome to ihangout

  37. bucweey34

    I havent posted on this board before. I have been watching since this past summer. I mainly post

    (6)
  38. Shelly2626

    Hah.. Love it .. We R due and so is the world in need FoMO tomorrow and beyond Great

    (1)
  39. calstang

    I agree that it could take 3 weeks for our EUA, but that IMO, would be very sad and yes, it would

    (5)
  40. Longestyard

    It's good to know if we ever run low on things to discuss we can always fill a solid week or two

  41. Goosebumps

    Dr. Patterson and Dr. Yos commercial presentation of their new collaboration for the Long

  42. viridi

    Was #3) Shorting the stock does not change the MOA of the molecule, and is therefore an asinine

    (3)
  43. CDiddy

    Haha! Love it.

  44. CTMedic

    Shelly, CDiddy and goosebumps (sorry if I left out any of our inveterate optimists) will lead the

    (7)
  45. Shelly2626

    It may have been the case up until this very quarter...but no longer is my opinion ....because

    (5)
  46. calstang

    It's unlikely many here will trust a comment made by you, when 1) this is your first comment

    (6)
  47. reallypeople?

    Its daytraders both long and short during the same day . DO NOT WORRY ABOUT SHORTS

    (1)
  48. chazzledazzle

    In the year 2000.

    (1)
  49. Rubraquercus

    As theories go, gestalt, yours is the best I recall.

  50. bucweey34

    Heres a theory. What if the shorts are bankrolled by some very deep pockets that want this

    (2)

Top 10 Most Recent News Articles

More News Articles

Top 5 Most Recently Viewed Articles

Gnosis Lab's Grand Re-Opening: A New Era for Diagnostics

Updated Category News Views 260

Gnosis Lab Grand Re-Opening Celebration Gnosis, a modern diagnostic laboratory previously known as Mountain View Medical Laboratory, is excited to announce its grand re-opening at its flagship location. This event signifies a crucial transition for the lab as it seeks to blend years of reliable community service with a fresh identity and enhanced capabilities. Commitment...

Continue Reading
New Propane Contract Boosts Titan NRG (TTNN) Growth

Updated Category Stocks Views 404

Titan NRG, Inc. Announces Major Propane Contract Secured Titan NRG, Inc. (OTC: TTNN) has a big contract for the 150,000 gallons of propane supply. Given to one of its subsidiaries, this contract represents a significant turning point for the business. Under this contract, propane will be delivered over the next year to a southern Arizona reservation. Crucially in securing...

Continue Reading
Bitcoin Price Decline: Impact of DOJ and Economic Conditions

Updated Category News Views 259

Bitcoin Price Experiences a Notable Decline Bitcoin has recently faced a serious downturn, falling to around $93,925 as fears surrounding U.S. interest rate changes and potential government sales of Bitcoin emerged. This has created a concerning environment for cryptocurrency investors, highlighting the volatility of digital assets. Market Sentiment and Economic Shifts...

Continue Reading
Cogitate and One Inc Team Up to Revolutionize Payments

Updated Category News Views 169

Cogitate Partners with One Inc to Transform Digital Payments -Customers Enjoy a Seamless Experience by Unifying All Payment Flows into One Comprehensive Platform- Cogitate, a provider of cloud-native core policy, billing, and claims applications for insurers, is excited to announce its partnership with One Inc, the leading digital payments network specifically for the...

Continue Reading
Alnylam Pharmaceuticals Achieves New Stock Milestone of $287.88

Updated Category News Views 74

Alnylam Pharmaceuticals Reaches Record Stock Price Alnylam Pharmaceuticals Inc. has recently made headlines after its stock price reached a remarkable all-time high of $287.88. This surge demonstrates a substantial increase in investor confidence, bolstered by an impressive 1-year change of 71.84% in the company's stock. Known for its groundbreaking work in RNA...

Continue Reading